Teva Pharmaceutical Industries (NYSE:TEVA) Issues Earnings Results, Beats Expectations By $0.01 EPS

Teva Pharmaceutical Industries (NYSE:TEVA) posted its earnings results on Wednesday. The company reported $0.53 earnings per share for the quarter, beating analysts’ consensus estimates of $0.52 by $0.01, FiscalAI reports. The business had revenue of $3.98 billion for the quarter, compared to analysts’ expectations of $3.85 billion. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The firm’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.52 earnings per share. Teva Pharmaceutical Industries updated its FY 2026 guidance to 2.570-2.770 EPS.

Here are the key takeaways from Teva Pharmaceutical Industries’ conference call:

• The company announced the acquisition of Amylyx to in-license ecopipam (Tourette’s) for $700 million upfront plus up to $200 million in milestones, expects ~80% product gross margin, closing late Q2/early Q3, and says the asset will be accretive to non-GAAP EPS starting in 2028 while not changing its 2027 leverage target.
• Teva’s innovative portfolio continues strong momentum with ~41% growth across key brands (Austedo ~+41%, UZEDY +62%, AJOVY +35%), Austedo guidance reiterated and management highlighting a multi-year path to >$2.5–3.0 billion peak sales.
• The pipeline is active with multiple near-term catalysts — positive duvakitug maintenance data already released, anti?IL?15 vitiligo readout in H1 and celiac in H2, DARI (asthma) Phase III events due by year?end, emrusolmin futility analysis by year?end, and olanzapine LAI regulatory progress — which management says represent >$10 billion of peak sales potential.
• Q1 results were mixed: revenue of ~$4.0 billion (down 1% reported, +7% ex?Japan and generic Revlimid), adjusted EBITDA $1.1 billion (+2%), non?GAAP EPS $0.53 (+2%), free cash flow materially improved (up ~76% to ~$200M), and net debt/EBITDA at ~2.42x.
• Transformation and capital-allocation priorities remain intact — on track for $700 million of cost savings by 2027 (about two?thirds expected by end?2026), recorded restructuring costs, board has authorized planning for a potential share buyback, and management reaffirms the goal of 30% non?GAAP operating margin and <2x net debt/EBITDA by 2027.

Teva Pharmaceutical Industries Price Performance

Teva Pharmaceutical Industries stock traded up $3.72 during trading hours on Wednesday, hitting $35.34. 22,280,120 shares of the stock were exchanged, compared to its average volume of 8,228,064. The company has a debt-to-equity ratio of 1.89, a quick ratio of 0.80 and a current ratio of 1.04. The stock has a market capitalization of $40.64 billion, a P/E ratio of 29.45, a P/E/G ratio of 2.75 and a beta of 0.76. Teva Pharmaceutical Industries has a 12 month low of $14.99 and a 12 month high of $37.35. The business’s 50-day moving average is $31.14 and its two-hundred day moving average is $29.29.

Key Stories Impacting Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Q1 beat and upbeat guidance: Teva reported $0.53 EPS on $3.98B revenue, topping estimates (consensus ~$0.52 EPS, ~$3.85B revenue) and pointed to FY?2026 EPS guidance of $2.57–$2.77 with revenue guidance roughly in line with Street expectations — investors view this as confirmation the pivot to branded/innovative growth is working. Reuters: Teva beats Q1 estimates
• Positive Sentiment: Strategic acquisition — Emalex Biosciences (ecopipam): Teva agreed to buy Emalex for $700M upfront (with potential additional contingent payments) to add an NDA?ready, first?in?class D1 antagonist for pediatric Tourette syndrome, accelerating growth in neurology and giving near?term commercial optionality if the NDA proceeds. Analysts (e.g., Jefferies) see strong strategic fit with Teva’s neuroscience business. Yahoo: Teva to Acquire Emalex
• Positive Sentiment: High-profile investor interest: David Einhorn has Teva near the top of a list of under?the?radar 2026 picks, which can attract additional institutional flows and validate the turnaround narrative. Yahoo: Einhorn likes Teva
• Positive Sentiment: Bullish market signals: Unusual options activity — heavy call buying — and large intraday volume point to speculative and institutional buying interest ahead of/after the earnings and deal news. (Company options activity note.)
• Neutral Sentiment: Earnings detail and analysis: Several outlets provide deeper metric breakdowns and slide decks for the Q1 print (sales mix, Medincell/UZEDY growth, lenalidomide generic headwinds) for investors doing fundamental follow?up. Zacks: Q1 metrics
• Neutral Sentiment: Management commentary: CEO interviews and the company slide deck describe execution on the pivot-to-growth strategy and timelines for the ecopipam NDA (anticipated 2H?2026), useful for timing expectations but not definitive proof of commercial success. YouTube: CEO interview
• Negative Sentiment: Deal cost and execution risk: The Emalex purchase is Teva’s largest in a decade (upfront $700M plus up to sizable contingent payments), which raises questions about cash use, integration risk and potential long?term return on the pay?up if commercial uptake or labeling is narrower than hoped. Investors should weigh that against Teva’s leverage (debt/equity) and capital allocation priorities. BioPharmaDive: Emalex deal analysis

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Bank of America upped their target price on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, April 9th. Jefferies Financial Group upped their price objective on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Monday, April 20th. Scotiabank upped their price objective on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a “sector outperform” rating in a research note on Thursday, January 29th. Finally, The Goldman Sachs Group upped their price objective on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $38.78.

Insider Activity at Teva Pharmaceutical Industries

In other news, CEO Richard D. Francis sold 442,935 shares of the company’s stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $32.36, for a total transaction of $14,333,376.60. Following the transaction, the chief executive officer directly owned 642,099 shares in the company, valued at approximately $20,778,323.64. This represents a 40.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Mark Sabag sold 62,102 shares of the company’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $30.14, for a total transaction of $1,871,754.28. Following the transaction, the insider owned 224,940 shares in the company, valued at $6,779,691.60. The trade was a 21.64% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 920,901 shares of company stock valued at $30,056,789 in the last three months. 0.54% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

A number of large investors have recently modified their holdings of TEVA. AQR Capital Management LLC lifted its position in shares of Teva Pharmaceutical Industries by 24.6% during the first quarter. AQR Capital Management LLC now owns 23,955 shares of the company’s stock worth $368,000 after purchasing an additional 4,732 shares in the last quarter. Focus Partners Wealth lifted its position in shares of Teva Pharmaceutical Industries by 4.5% during the first quarter. Focus Partners Wealth now owns 40,074 shares of the company’s stock worth $616,000 after purchasing an additional 1,739 shares in the last quarter. Franklin Resources Inc. acquired a new position in shares of Teva Pharmaceutical Industries during the second quarter worth approximately $255,000. Flow Traders U.S. LLC acquired a new position in shares of Teva Pharmaceutical Industries during the second quarter worth approximately $238,000. Finally, Cerity Partners LLC lifted its position in shares of Teva Pharmaceutical Industries by 2.9% during the second quarter. Cerity Partners LLC now owns 45,837 shares of the company’s stock worth $768,000 after purchasing an additional 1,291 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.